Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model

Journal of Pharmacological Sciences

Volumn 119, Issue 1, 2012, Pages 10-19

  Inden, Masatoshi ^a,d   Abe, Mari ^a   Minamino, Hideaki ^a   Takata, Kazuyuki ^a   Yoshimoto, Kanji ^b   Tooyama, Ikuo ^c   Kitamura, Yoshihisa ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d RITSUMEIKAN UNIVERSITY   (Japan)

Author keywords

6 Hydroxydopamine; Fluoxetine; L dihydroxyphenylalanine; Parkinson's disease; Selective serotonin reuptake inhibitor

Indexed keywords

FLUOXETINE; HISTONE H3; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; OXIDOPAMINE; SEROTONIN 1A RECEPTOR; TRYPTOPHAN HYDROXYLASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NERVE CELL; NONHUMAN; PARKINSONISM; PROTEIN PHOSPHORYLATION; RAPHE NUCLEUS; RAT; SEROTONINERGIC SYSTEM; SUBSTANTIA NIGRA;

EID: 84861468507     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12003FP     Document Type: Article

References (48)

1. Ng KY, Colburn RW, Kopin IJ. L-DOPA-induced release of cerebral monoamines. Science. 1970;170:76-77.
2. Hollister AS, Breese GR, Mueller RA. Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity. J Pharmacol Exp Ther. 1979;208:37-43. (Pubitemid 9175825)
3. Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I. Immuno-histochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res. 1994;667:295-299.
4. Maeda T, Nagata K, Yoshida Y, Kannari K. Serotonergic hyperin-nervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered 1-DOPA. Brain Res. 2005;1046:230-233. (Pubitemid 40775894)
5. Carta M, Carlsson T, KiriK D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007;130:1819-1833. (Pubitemid 47343795)
6. Munoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain. 2008;131:3380-3394.
7. Carlsson T, Carta M, Winkler C, Björklund A, Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci. 2007;27:8011-8022. (Pubitemid 47173327)
8. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5:235-245. (Pubitemid 43238347)
9. Vajda FJ, Solinas C. Current approaches to management of depression in Parkinson's disease. J Clin Neurosci. 2005;12: 739-743. (Pubitemid 41411876)
10. Weintraub D, Comella CL, Horn S. Parkinson's disease - Part 3: Neuropsychiatric symptoms. Am J Manag Care. 2008; 14 (2 Suppl):S59-S69.
11. van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol. 2002;26:142-145.
12. Arbouw M, Moving K, Neef C, Guchelaar HJ, Egberts T. Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients. Eur J Clin Pharmacol. 2007;63:181-187. (Pubitemid 46147060)
13. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970;24:485-493.
14. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol. 2002;175:303-317. (Pubitemid 34634286)
15. Shimohama S, Sawada H, Kitamura Y, Taniguchi T. Disease model: Parkinson's disease. Trends Mol Med. 2003;9:360-365.
16. van Kampen JM, Stoess AJ. Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience. 2003;116:307-314.
17. Thomas H, Huganir RL. MAPK cascade signaling and synaptic plasticity. Nat Rev Neurosci. 2004;5:173-183. (Pubitemid 38252474)
18. Pavon N, Martin AB, Mendialdua A, Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry. 2006;59:64-74. (Pubitemid 43005237)
19. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, et al. Critical involvement of c AMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci. 2007;27:6995-7005. (Pubitemid 47015907)
20. Santini E, Alcacer C, Cacciatore S, Heiman M, Hervé D, Greengard P, et al. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem. 2009;108:621-633.
21. Yamato H, Kannari K, Shen H, Suda T, Matsunaga M. Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport. 2001;12:1123-1126. (Pubitemid 32374729)
22. Inden M, Taira T, Kitamura Y, Yanagida T, Tsuchiya T, Takata K, et al. PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model. Neurobiol Dis. 2006;24:144-158. (Pubitemid 44416214)
23. Soloaga A, Thomson S, Wiggin GR, Rampersaund N, Dyson MH, Hazzakin CA, et al. MSK2 and MSK1 mediate the mitogen and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J. 2003;22:2788-2797.
24. Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol. 1980;8:558-563. (Pubitemid 11213498)
25. Hefti F, Melamed E, Wurtman RJ. The site of dopamine formation in rat striatum after L-dopa administration. J Pharmacol Exp Ther. 1981;217:189-197. (Pubitemid 11103843)
26. Tanaka H, Kannari K, Maeda T, Tomiyama M, Sudo T, Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport. 1999;10:631-634. (Pubitemid 29333295)
27. Parent M, Wallman MJ, Gagnon D, Parent A. Serotonin innervation of basal ganglia in monkeys and humans. J Chem Neuroanat. 2011;41:256-265.
28. Wallman MJ, Gagnon D, Parent M. Serotonin innervation of human basal ganglia. Eur J Neurosci. 2011;33:1519-1532.
29. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther. 2007;113:296-320. (Pubitemid 46149046)
30. Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson's disease. Prog Neurobiol. 2011;95:163-212.
31. Artigas F. 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci. 1993;14:262. (Pubitemid 23204242)
32. Sharp T, Bramwell SR, Grahame-Smith DG. 5-HT1 agonists reduce 6-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol. 1989;96: 283-290 (Pubitemid 19045101)
33. Casanovas JM, Lesourd M, Artigas F. The effect of the selective 5-HT1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain. Br J Pharmacol. 1997;122:733-741. (Pubitemid 27453100)
34. Kreitzer AC. Physiology and pharmacology of striatal neurons. Annu Rev Neurosci. 2009;32:127-147.
35. Darmopil S, Martin AB, De Diego IR, Ares S, Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry. 2009;66:603-613.
36. Delfino MA, Stefano AV, Ferrario JE, Taravini IR, Murer MG, Gershanik OS. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. Behav Brain Res. 2004;152:297-306. (Pubitemid 38757900)
37. Monville C, Torres EM, Dunnett SB. Validation of the L-DOPA-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res Bull. 2005;68:16-23. (Pubitemid 41698872)
38. Taylor JL, Bishop C, Walker PD. Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol Biochem Behav. 2005;81:887-893. (Pubitemid 41187824)
39. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA. Spatiotemporal pattern of striatal ERM1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry. 2007;62:800-810. (Pubitemid 47374647)
40. Carta AR, Frau L, Pinna A, Pontis S, Simola N, Schintu N, et al. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse. 2008;62:524-533. (Pubitemid 351794179)
41. Goulet M, Grondin R, Blanchet PJ, Bedard PJ, Di Paolo T. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naïve MPTP monkeys. Brain Res. 1996;719:129-137. (Pubitemid 26173384)
42. Calon F, Morissette M, Goulet M, Grondin R, Blanchet PJ, Bedard PJ, et al. Chronic D1 and D2 dopaminomimetic of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/ benzodiazepine receptor complex and GABA content. Neurochem Int. 1999;35:81-91. (Pubitemid 29251232)
43. Rascol O, Nutt JG, Blin O, Goetz CG, Trugman JM, Soubrouilland C, et al. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson's disease. Arch Neurol. 2001;58:249-254. (Pubitemid 32163162)
44. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci. 2007;8: 355-367. (Pubitemid 46652469)
45. Deng H, Bao X, Cai W, Blacketer MJ, Belmont AS, Girton J, et al. Ectopic histone H3S10 phosphorylation causes chromatin structure remodeling in Drosophila. Development. 2008;135: 699-705. (Pubitemid 351405023)
46. Cheung P, Allis CD, Sassone-Corsi P. Signaling to chromatin through histone modification. Cell. 2000;103:263-271.
47. Brami-Cherrier K, Roze E, Girault JA, Betuing S, Caboche J. Role of the ERK/MSK1 signaling pathway in chromatin remodeling and brain responses to drugs of abuse. J Neurochem. 2009;108:1323-1335.
48. Santini E, Valjent E, Fisone G. Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J. 2008; 275:1392-1399. (Pubitemid 351388785)